<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Peginterferon alfa-2b</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00022</strong>&#160; (BIOD00048, BTD00048)</td></tr><tr><th>Type</th><td>biotech</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Peginterferon alfa-2b is a covalent conjugate of recombinant alfa-2b interferon with monomethoxy polyethylene glycol (<span class="caps">PEG</span>). The average molecular weight of the <span class="caps">PEG</span> portion of the molecule is 12,000 daltons. The average molecular weight of the <span class="caps">PEG</span>-Intron molecule is approximately 31,000 daltons. The specific activity of peginterferon alfa-2b is approximately 0.7 &#215; 108 IU/mg protein. Interferon alfa-2b is a water-soluble protein with a molecular weight of 19,271 daltons produced by recombinant <span class="caps">DNA</span> techniques. It is obtained from the bacterial fermentation of a strain of <i>Escherichia coli</i> bearing a genetically engineered plasmid containing an interferon gene from human leukocytes. The <span class="caps">PEG</span> strand protects the molecule in vivo from proteolytic breakdown, substantially increases its in vivo half-life, and reduces immunogenicity by wrapping around and physically hindering access to the protein portion of the molecule.</p></td></tr><tr><th>Protein structure</th><td><a href="/system/protein_structures/full/DB00022.png?1266600385"><img alt="Db00022" src="/system/protein_structures/thumb/DB00022.png?1266600385"></a></td></tr><tr><th>Protein chemical formula</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein average weight</th><td>31000.0000</td></tr><tr><th>Sequences</th><td><pre class="sequence">&gt;DB00022 sequence
CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI
QQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVR
KYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE</pre><small><a class="btn btn-info btn-sm" href="/drugs/DB00022/polypeptide_sequences.fasta">Download FASTA Format</a></small></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>PEG-Intron</td><td>Schering Corp</td></tr><tr><td>PegIntron</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Unitron PEG</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/immunosuppressive-agents">Immunosuppressive Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>99210-65-8</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>Peptides</td></tr><tr><th>Alternative parents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Substituents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Classification description</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of chronic hepatitis C in patients not previously treated with interferon alpha who have compensated liver disease and are at least 18 years of age.</td></tr><tr><th>Pharmacodynamics</th><td>Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R.</td></tr><tr><th>Mechanism of action</th><td>Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.</td></tr><tr><th>Absorption</th><td>Following a single subcutaneous dose of peginterferon alfa-2b, the mean absorption half-life (t&#189; k<sub>a</sub>) was 4.6 hours.
</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"></td></tr><tr><th>Route of elimination</th><td>Renal elimination accounts for 30% of the clearance.</td></tr><tr><th>Half life</th><td>The mean elimination half-life is approximately 40 hours (range 22 to 60 hours) in patients with HCV infection.

</td></tr><tr><th>Clearance</th><td><ul>
	<li>Oral cl=22 mL/hr&#8729;kg [patients with <span class="caps">HCV</span> infection]</li>
</ul></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.schering.de">Schering Corp.</a></li>
<li><a href="http://www.schering-plough.ca">Schering-Plough Inc.</a></li>
<li><a href="http://www.vetter-pharma.com">Vetter Pharma Fertigung GmbH and Co. KG</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Powder, for solution</td><td>Subcutaneous</td><td></td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Peg-Intron Redipen Pak 4 4 50 mcg/0.5ml Kit Box</td><td>2428.8USD</td><td>kit</td></tr><tr><td>Peg-Intron Redipen 150 mcg/0.5ml Kit</td><td>702.87USD</td><td>kit</td></tr><tr><td>Peg-Intron 150 mcg Kit</td><td>671.74USD</td><td>kit</td></tr><tr><td>Peg-Intron Redipen 120 mcg/0.5ml Kit</td><td>669.39USD</td><td>kit</td></tr><tr><td>Peg-Intron redipen 150 mcg</td><td>640.61USD</td><td>redipen</td></tr><tr><td>Peg-Intron redipen 150 mcg 4pk</td><td>640.6USD</td><td>redipen</td></tr><tr><td>Peg-Intron 120 mcg Kit</td><td>639.74USD</td><td>kit</td></tr><tr><td>Peg-Intron Redipen 80 mcg/0.5ml Kit</td><td>637.49USD</td><td>kit</td></tr><tr><td>Peg-Intron redipen 120 mcg</td><td>610.09USD</td><td>redipen</td></tr><tr><td>Peg-Intron 80 mcg Kit</td><td>609.26USD</td><td>kit</td></tr><tr><td>Peg-Intron 50 mcg/0.5ml Kit</td><td>607.19USD</td><td>kit</td></tr><tr><td>Peg-Intron redipen 80 mcg</td><td>581.02USD</td><td>redipen</td></tr><tr><td>Peg-Intron 50 mcg kit</td><td>553.4USD</td><td>kit</td></tr><tr><td>Peg-Intron redipen 50 mcg</td><td>553.4USD</td><td>redipen</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>Canada</td><td>1341567</td><td>2008-02-19</td><td>2025-02-19</td></tr><tr><td>Canada</td><td>2329474</td><td>0002-02-26</td><td>2016-10-31</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>liquid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>61 &#176;C</td><td>Beldarrain, A. et al., Biochemistry 38:7865-7873 (1999)</td></tr><tr><td>isoelectric point</td><td>5.99</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></table></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>General Reference</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>UniProt</td><td><a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P01563" target="_blank">P01563 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA164784024" target="_blank">PA164784024 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=2242966" target="_blank">2242966 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic2/peginterferon.htm" target="_blank">http://www.rxlist.com/cgi/generic2/peginterferon.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/peginterferon-alfa-2b.html" target="_blank">http://www.drugs.com/cdi/peginterferon-alfa-2b.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Peginterferon_alfa-2b" target="_blank">Peginterferon_alfa-2b <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>L03AB10<ul class="atc-drug-tree"><li><a href="/atc/L#L">L &#8212; ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</a></li><li><a href="/atc/L03#L03">L03 &#8212; IMMUNOSTIMULANTS</a></li><li><a href="/atc/L03A#L03A">L03A &#8212; IMMUNOSTIMULANTS</a></li><li><a href="/atc/L03AB#L03AB">L03AB &#8212; Interferons</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>08:18.20</li></ul></td></tr><tr><th>PDB Entries</th><td><ul><li><a class="wishart-link-out" href="http://www.rcsb.org/pdb/explore.do?structureId=1ITF" target="_blank">1ITF <span class="glyphicon glyphicon-new-window"> </span></a></li></ul></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB00022.pdf?1265922813">show</a>(50.9 KB)</td></tr><tr><th>MSDS</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01223">Aminophylline</a></td><td>Interferon increases the effect and toxicity of theophylline</td></tr><tr><td><a href="/drugs/DB00651">Dyphylline</a></td><td>Interferon increases the effect and toxicity of theophylline</td></tr><tr><td><a href="/drugs/DB01303">Oxtriphylline</a></td><td>Interferon increases the effect and toxicity of theophylline</td></tr><tr><td><a href="/drugs/DB00277">Theophylline</a></td><td>Interferon increases the effect and toxicity of theophylline</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>